Literature DB >> 16091231

Management of HIV-infected patients with multidrug-resistant virus.

Marianne Harris1, Julio S G Montaner.   

Abstract

Treatment-experienced patients with HIV may harbor virus that has accumulated several mutations conferring decreased susceptibility to one or more antiretroviral drugs. For clinicians treating these patients, identifying a tolerable antiretroviral regimen with a reasonable chance of a durable virologic effect represents a major challenge. The first priority is to identify and correct the mechanisms responsible for previous treatment failure. Resistance testing and drug level monitoring may be useful in this setting. The patient's history of antiretroviral drug tolerability, comorbidities, and concomitant medications should be considered. Patients embarking on multiple-drug regimens will require close monitoring for adherence, toxicities, and drug-drug interactions. The guiding principle when constructing a rescue or salvage regimen is to achieve a cumulative activity score greater than 2, recognizing that some agents will have only partial activity. Some new drugs are available that may be helpful if used carefully with an active background regimen.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 16091231     DOI: 10.1007/s11904-004-0017-8

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.071


  27 in total

1.  Unfavourable interaction of amprenavir and lopinavir in combination with ritonavir?

Authors:  Stefan Mauss; Guenther Schmutz; Dieter Kuschak
Journal:  AIDS       Date:  2002-01-25       Impact factor: 4.177

Review 2.  Therapeutic drug monitoring in HIV infection: current status and future directions.

Authors:  David Back; Giorgio Gatti; Courtney Fletcher; Rodolphe Garaffo; Richard Haubrich; Richard Hoetelmans; Michael Kurowski; Andrew Luber; Concepta Merry; Carlo-Federico Perno
Journal:  AIDS       Date:  2002-03       Impact factor: 4.177

3.  Pharmacokinetic interaction between lopinavir/r and amprenavir in salvage therapy.

Authors:  Stéphanie Basso; Caroline Solas; Anne-Marie Quinson; Isabelle Ravaux; Isabelle Poizot-Martin; J Bacconier; Alain Durand; Bruno Lacarelle
Journal:  J Acquir Immune Defic Syndr       Date:  2002-09-01       Impact factor: 3.731

4.  Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure.

Authors:  V Miller; C Sabin; K Hertogs; S Bloor; J Martinez-Picado; R D'Aquila; B Larder; T Lutz; P Gute; E Weidmann; H Rabenau; A Phillips; S Staszewski
Journal:  AIDS       Date:  2000-12-22       Impact factor: 4.177

5.  Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.

Authors:  R S Hogg; B Yip; K J Chan; E Wood; K J Craib; M V O'Shaughnessy; J S Montaner
Journal:  JAMA       Date:  2001-11-28       Impact factor: 56.272

6.  Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens.

Authors:  J S Montaner; P R Harrigan; N Jahnke; J Raboud; E Castillo; R S Hogg; B Yip; M Harris; V Montessori; M V O'Shaughnessy
Journal:  AIDS       Date:  2001-01-05       Impact factor: 4.177

7.  Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.

Authors:  Martin S Hirsch; Françoise Brun-Vézinet; Bonaventura Clotet; Brian Conway; Daniel R Kuritzkes; Richard T D'Aquila; Lisa M Demeter; Scott M Hammer; Victoria A Johnson; Clive Loveday; John W Mellors; Donna M Jacobsen; Douglas D Richman
Journal:  Clin Infect Dis       Date:  2003-06-23       Impact factor: 9.079

8.  Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial.

Authors:  Kathleen Squires; Anton L Pozniak; Gerald Pierone; Corklin R Steinhart; Daniel Berger; Nicholaos C Bellos; Stephen L Becker; Michael Wulfsohn; Michael D Miller; John J Toole; Dion F Coakley; Andrew Cheng
Journal:  Ann Intern Med       Date:  2003-09-02       Impact factor: 25.391

9.  Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity.

Authors:  Steven Coca; Mark A Perazella
Journal:  Am J Med Sci       Date:  2002-12       Impact factor: 2.378

10.  HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV cohort.

Authors:  V Miller; A Cozzi-Lepri; K Hertogs; P Gute; B Larder; S Bloor; S Klauke; H Rabenau; A Phillips; S Staszewski
Journal:  Antivir Ther       Date:  2000-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.